Trial Profile
A Single-Center, Randomized, Open-Label, Parallel-Group, Placebo-Controlled, Cross-Over Study To Investigate the Impact of Speed of Injection and Site of Injection on Pain, Tolerability, Safety, and Pharmacokinetics Following Subcutaneous Administration of Gantenerumab in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Roche
- 27 Apr 2023 Results from NCT02882009 and NCT04592341 assessing value and feasibility of subcutaneous administration of Gantenerumab , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 26 Dec 2019 Results published in the Clinical Therapeutics
- 15 Jun 2017 Status changed from recruiting to completed.